healthletic bpc-157 third party testing Peptide BPC-157 Supplement | Gut, Joint

de Oliveira, C

It is not a drug, food, cosmetic, or dietary supplement, has not been evaluated by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease

Synergy: The combination covers both the localized repair signal and the systemic mobilization response, producing faster and higher-quality healing than either peptide alone

Monitor for any return of symptoms and adjust accordingly

Tirzepatide is a dual-agonist , meaning it works by targeting two hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Retatrutide is a triple-agonist , meaning it targets three hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Glucagon: affects energy use and fat metabolism Early studies show that retatrutide may be more successful than tirzepatide at managing diabetic kidney disease, as well as for weight control, while tirzepatide may be better at managing blood glucose

Together, this combination is commonly used in regenerative and recovery-focused protocols to support musculoskeletal repair, soft tissue healing, and overall recovery